Experience

Iksuda Therapeutics

• United Kingdom
• Biotechnology Research
• 1 - 100 Employee

• • Oct 2021 - Present

  • Recruit, develop and lead two high-performing, multi-disciplinary teams of Bioconjugation Scientists and Cell Biologists to generate differentiated ADCs for clinical phase testing. • Design and support workplans and timelines for numerous projects, including the validation of novel ADCs by screening properties by HPLC, SDS-PAGE, mass spectrometry, FACS, SDS-PAGE and the development of robust cell-based platforms for screening the potency of novel ADCs and toxins through in vitro cell viability assays.• Liaise with external parties for the successful completion of projects including, antibody production, in vivo efficacy (mice), in vivo tolerability studies (cynomolgus monkey), mass spectrometry • Support BD and Director of Research with strategy and identifying opportunities to collaborate, partner and/or in-license technologies/platforms and ADCs at pre-clinical/clinical stage as required.• Development of company intellectual property through drafting patent applications. Show less

• • Mar 2020 - Oct 2021

  Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs).Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.We are building a pipeline of ADCs centred on:• PermaLink® – proprietary conjugation chemistry for improved ADC stability• Novel ultra-potent toxins for improved tumour killing• Novel antibodies targeted towards well-selected antigens associated primarily with solid tumoursWe are focused on providing more effective treatments for patients who have few options, with a particular focus on solid tumours such as lung, ovarian, cervix, pancreatic and colorectal.Our first wave ADC programmes include antibodies with proven premise in ADC formats and novel DNA damaging payloads.We are working with leading research institutions in the US and Europe to develop exciting new therapies for the future. We are flexible in our approach to collaboration and welcome discussions with research groups who have novel ADC-relevant programmes.We have developed a series of high-value ADC assets, which are available for collaborative research and license. Show less

• • Jul 2016 - Mar 2020